Gelesis Holdings Inc.
Gelesis Holdings, Inc., a commercial stage biotherapeutics company, developing a biomimicry to treat the genesis of obesity and GI-related chronic diseases. It also offers PLENITY, an orally administered, non-stimulant, and non-systemic aid for weight management. In addition, the company develops GS200 for weight loss in prediabetes and type 2 diabetes; and GS500 for functional constipation. Furt… Read more
Gelesis Holdings Inc. (GLSHQ) - Net Assets
Latest net assets as of June 2023: $-18.62 Million USD
Based on the latest financial reports, Gelesis Holdings Inc. (GLSHQ) has net assets worth $-18.62 Million USD as of June 2023.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($95.88 Million) and total liabilities ($114.50 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-18.62 Million |
| % of Total Assets | -19.43% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
Gelesis Holdings Inc. - Net Assets Trend (2020–2022)
This chart illustrates how Gelesis Holdings Inc.'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Gelesis Holdings Inc. (2020–2022)
The table below shows the annual net assets of Gelesis Holdings Inc. from 2020 to 2022.
| Year | Net Assets | Change |
|---|---|---|
| 2022-12-31 | $-12.47 Million | -- |
| 2021-12-31 | $0.00 | -- |
| 2020-12-31 | $235.37 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Gelesis Holdings Inc.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 30734014000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2022)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $7.00K | % |
| Other Comprehensive Income | $104.00K | % |
| Other Components | $297.47 Million | % |
| Total Equity | $-25.06 Million | 100.00% |
Gelesis Holdings Inc. Competitors by Market Cap
The table below lists competitors of Gelesis Holdings Inc. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Philippine Seven Corp
PSE:SEVN
|
$5.66K |
|
J Smart Co Contractors PLC
LSE:SMJ
|
$5.67K |
|
Brooge Energy Limited
NASDAQ:BROGW
|
$5.67K |
|
Perseverance Metals Inc.
V:PMI
|
$5.67K |
|
NOODLES & CO-A
BE:NO3
|
$5.65K |
|
Body One SA
PA:MLONE
|
$5.65K |
|
Canamex Gold Corp
PINK:CNMXF
|
$5.64K |
|
Central Container JSC
VN:VSM
|
$5.64K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Gelesis Holdings Inc.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2021 to 2022, total equity changed from -329,836,000 to -25,056,000, a change of 304,780,000.
- Net loss of 57,128,000 reduced equity.
- New share issuances of 39,000 increased equity.
- Other comprehensive income decreased equity by 115,000.
- Other factors increased equity by 361,984,000.
Equity Change Factors (2021 to 2022)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-57.13 Million | -228.0% |
| Share Issuances | $39.00K | +0.16% |
| Other Comprehensive Income | $-115.00K | -0.46% |
| Other Changes | $361.98 Million | +1444.7% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Gelesis Holdings Inc.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2020-12-31 | $6.82 | $0.00 | x |
| 2021-12-31 | $-57.74 | $0.00 | x |
| 2022-12-31 | $-0.36 | $0.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Gelesis Holdings Inc. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -221.71%
- • Asset Turnover: 0.25x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-2.17%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2020 | -6.50% | 0.00% | 0.00x | 1.18x | $-38.83 Million |
| 2021 | 0.00% | -837.93% | 0.08x | 0.00x | $-60.74 Million |
| 2022 | 0.00% | -221.71% | 0.25x | 0.00x | $-54.62 Million |
Industry Comparison
This section compares Gelesis Holdings Inc.'s net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Gelesis Holdings Inc. (GLSHQ) | $-18.62 Million | -6.50% | N/A | $5.66K |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |